Copyright
©The Author(s) 2023.
World J Gastroenterol. Jul 21, 2023; 29(27): 4289-4316
Published online Jul 21, 2023. doi: 10.3748/wjg.v29.i27.4289
Published online Jul 21, 2023. doi: 10.3748/wjg.v29.i27.4289
Table 1 Blood pressures and thrombosis in rats at 15 min and 60 min following stomach perforation
Application of the 1 mL/rat through the perforated defect in the injured stomach at 5 min following perforation | Blood pressures and thrombosis in rats at 15 min and 60 min following stomach perforation | |
15 min | 60 min | |
Superior sagittal sinus pressure, mmHg, mean ± SD | ||
Control | 9 ± 1 | 8 ± 1 |
BPC 157 10 μg/kg | -3 ± 1a | -1 ± 1a |
BPC 157 10 ng/kg | -1 ± 1a | -2 ± 1a |
Portal pressure, mmHg, mean ± SD | ||
Control | 16 ± 2 | 17 ± 1 |
BPC 157 10 μg/kg | 9 ± 1a | 9 ± 1a |
BPC 157 10 ng/kg | 9 ± 1a | 8 ± 1a |
Caval pressure, mmHg, mean ± SD | ||
Control | 15 ± 1 | 15 ± 1 |
BPC 157 10 μg/kg | 8 ± 1 | 9 ± 1a |
BPC 157 10 ng/kg | 7 ± 1 | 9 ± 1a |
Aortal pressure, mmHg, mean ± SD | ||
Control | 42 ± 5 | 45 ± 7 |
BPC 157 10 μg/kg | 75 ± 4a | 72 ± 5a |
BPC 157 10 ng/kg | 80 ± 5a | 78 ± 7a |
Superior sagittal sinus, thrombus mass, g, mean ± SD | ||
Control | 0.0012 ± 0.0005 | 0.0022 ± 0.0009 |
BPC 157 10 μg/kg | 0 ± 0a | 0 ± 0a |
BPC 157 10 ng/kg | 0 ± 0a | 0 ± 0a |
Portal vein, thrombus mass, g, mean ± SD | ||
Control | 0.0034 ± 0.0006 | 0.0056 ± 0.0008 |
BPC 157 10 μg/kg | 0.0010 ± 0.0005a | 0.0020 ± 0.0005a |
BPC 157 10 ng/kg | 0.0010 ± 0.0007a | 0.0018 ± 0.0006a |
Inferior caval vein, thrombus mass, g, mean ± SD | ||
Control | 0.0039 ± 0.0007 | 0.0061 ± 0.0008 |
BPC 157 10 μg/kg | 0.0002 ± 0.0001a | 0.0003 ± 0.0001a |
BPC 157 10 ng/kg | 0.0008 ± 0.0001a | 0.0005 ± 0.0002a |
Abdominal aorta, thrombus mass, g, mean ± SD | ||
Control | 0.0044 ± 0.0007 | 0.0063 ± 0.0009 |
BPC 157 10 μg/kg | 0 ± 0a | 0 ± 0a |
BPC 157 10 ng/kg | 0 ± 0a | 0 ± 0a |
Table 2 Relative volume of the stomach of the heart, azygos vein, in rats at 5 min and 15 min following stomach perforation
0 min | 5 min | 5 min | 15 min |
Relative volume (healthy/perforation, %) of the stomach in rats immediately after perforation | Application of the 1 mL/rat through the perforated defect in the injured stomach at 5 min following perforation | Relative volume (healthy/perforation, healthy/perforation + therapy, %) of the stomach, in rats at 5 min and 15 min following stomach perforation | |
Relative volume (healthy/perforation, %) of the stomach, mean ± SD | Medication | Relative volume (healthy/perforation + therapy, %) of the stomach, mean ± SD | |
100 ± 3 | Saline 5 mL/kg (control) | 114 ± 2a,b | 118 ± 2a,b |
100 ± 2 | BPC 157 10 μg/kg | 87 ± 5a,b,c | 76 ± 8a,b,c |
101 ± 2 | BPC 157 10 ng/kg | 81 ± 7a,b,c | 79 ± 9a,b,c |
Table 3 Relative volume of the brain, inferior caval vein, and superior mesenteric vein, and relative volume of the heart, azygos vein, in rats at 15 min and 60 min following stomach perforation
0 min | 5 min | 15 min | 60 min |
Relative volume (healthy/perforation, %) of the brain, heart, azygos vein, inferior caval vein, superior mesenteric vein, and abdominal aorta in rats immediately after perforation | Application of the 1 mL/rat through the perforated defect in the injured stomach at 5 min following perforation | Relative volume (healthy/perforation, healthy/perforation + therapy, %) of the brain, inferior caval vein, and superior mesenteric vein, and relative volume (control/treated, %) of the heart, azygos vein, in rats at 15 min and 60 min following stomach perforation | |
Relative volume (healthy/perforation) (%) of the brain, mean ± SD | Medication | Relative volume (healthy/perforation + therapy, %) of the brain, mean ± SD | |
116 ± 3a | Saline 5 mL/kg (control) | 124 ± 2a,b | 124 ± 2a,b |
120 ± 2a | BPC 157 10 μg/kg | 100 ± 1b,c | 99 ± 2b,c |
121 ± 2a | BPC 157 10 ng/kg | 101 ± 3b,c | 100 ± 1b,c |
- | Relative volume (control/treated, %) of the heart, mean ± SD | ||
BPC 157 10 μg/kg | 137 ± 4c | 141 ± 5c | |
BPC 157 10 ng/kg | 136 ± 3c | 138 ± 4c | |
Relative volume (control/treated, %) of the azygos vein, mean ± SD | |||
BPC 157 10 μg/kg | 66 ± 6c | 58 ± 7c | |
BPC 157 10 ng/kg | 64 ± 4c | 54 ± 8c | |
Relative volume (healthy/perforation + therapy, %) of the inferior caval vein, mean ± SD | |||
130 ± 3a | Saline 5 mL/kg (control) | 164 ± 8a,b | 174 ± 9a,b |
128 ± 4a | BPC 157 10 μg/kg | 98 ± 2b,c | 100 ± 2b,c |
126 ± 4a | BPC 157 10 ng/kg | 100 ± 3b,c | 99 ± 1b,c |
Relative volume (healthy/perforation + therapy, %) of the superior mesenteric vein, mean ± SD | |||
180 ± 5a | Saline 5 mL/kg (control) | 204 ± 8a,b | 212 ± 9a,b |
188 ± 9a | BPC 157 10 μg/kg | 96 ± 6b,c | 99 ± 7b,c |
186 ± 8a | BPC 157 10 ng/kg | 98 ± 6b,c | 101 ± 1b,c |
Table 4 ECG changes, PQ interval, QTc interval, msec, heart frequency, beats/min, in rats at 15 min and 60 min following stomach perforation
Application of the 1 mL/rat through the perforated defect in the injured stomach at 5 min following perforation | ECG changes in rats at 15 min and 60 min following stomach perforation | |
15 min | 60 min | |
PQ interval, msec mean ± SD | ||
Control | 64 ± 5 | 67 ± 6 |
BPC 157 10 μg/kg | 50 ± 5a | 50 ± 5a |
BPC 157 10 ng/kg | 50 ± 5a | 50 ± 5a |
QTc interval, msec, mean ± SD | ||
Control | 312 ± 10 | 347 ± 10 |
BPC 157 10 μg/kg | 180 ± 10a | 188 ± 10a |
BPC 157 10 ng/kg | 185 ± 10a | 183 ± 10a |
Heart frequency, beats/min, mean ± SD | ||
Control | 530 ± 30 | 550 ± 30 |
BPC 157 10 μg/kg | 375 ± 10 a | 360 ± 10a |
BPC 157 10 ng/kg | 385 ± 10 a | 365 ± 10a |
Table 5 Lesions scored microscopically (heart, lung, liver, kidney, stomach), or macroscopically (stomach, in rats at 15 min and 60 min following stomach perforation
Application of the 1 mL/rat through the perforated defect in the injured stomach at 5 min following perforation | Lesions scored microscopically (heart, lung, liver, kidney, stomach, small and large intestine), or macroscopically (stomach), in rats at 15 min and 60 min following stomach perforation | |
15 min | 60 min | |
Heart (scored 0-3, min/med/max) | ||
Control | 3/3/3 | 3/3/3 |
BPC 157 10 μg/kg | 0/0/0a | 0/0/0a |
BPC 157 10 ng/kg | 0/0/0a | 0/0/0a |
Lung (scored 0-3, min/med/max) | ||
Control | 3/3/3 | 3/3/3 |
BPC 157 10 μg/kg | 1/1/1a | 1/1/1a |
BPC 157 10 ng/kg | 1/1/1a | 1/1/1a |
Liver (scored 0-3, min/med/max) | ||
Control | 3/3/3 | 3/3/3 |
BPC 157 10 μg/kg | 0/0/0a | 0/0/0a |
BPC 157 10 ng/kg | 0/0/0a | 0/0/0a |
Kidney (scored 0-3, min/med/max) | ||
Control | 3/3/3 | 3/3/3 |
BPC 157 10 μg/kg | 0/0/0a | 0/0/0a |
BPC 157 10 ng/kg | 0/0/0a | 0/0/0a |
Stomach (scored 0-15, min/med/max) | ||
Control | 5/5/5 | 4/5/5 |
BPC 157 10 μg/kg | 1/1/1a | 1/1/1a |
BPC 157 10 ng/kg | 1/1/1a | 1/1/1a |
Table 6 Lesions were assessed microscopically (cerebrum, cerebellum, hypothalamus, hippocampus), in rats at 15 min and 60 min following stomach perforation
Application of the 1 ml/rat through the perforated defect in the injured stomach at 5 min following perforation | Lesions scored microscopically cerebrum, cerebellum, hypothalamus, and hippocampus in rats at 15 min and 60 min following stomach perforation | |
15 min | 60 min | |
Cerebrum (scored 0-8, min/med/max); percentage of karyopycnotic cells (%), mean ± SD | ||
Control | 2/2/2; 30 ± 5 | 2/2/2, 35 ± 5 |
BPC 157 10 μg/kg | 0/1/1a, 5 ± 5a | 0/1/1a, 5 ± 5a |
BPC 157 10 ng/kg | 0/1/1a, 5 ± 5a | 0/1/1a, 5 ± 5a |
Neuronal damage in the karyopyknotic areas, %, mean ± SD (10 HPF, 400 ×) | ||
Control | 39 ± 5 | 42 ± 4 |
BPC 157 10 μg/kg | 2 ± 2a | 3 ± 2a |
BPC 157 10 ng/kg | 2 ± 2a | 2 ± 2a |
Hemorrhage (% of total area), mean ± SD | ||
Control | 30 ± 2 | 25 ± 2 |
BPC 157 10 μg/kg | 5 ± 2a | 5 ± 2a |
BPC 157 10 ng/kg | ||
Edema (scored 0-3, min/med/max) | ||
Control | 37683 | 37683 |
BPC 157 10 μg/kg | 1/1/1a | 1/1/1a |
BPC 157 10 ng/kg | 1/1/1a | 1/1/1a |
Cerebellum (scored 0-8, min/med/max); percentage of karyopycnotic cells (%), mean ± SD | ||
Control | 1/2/2, 13 ± 5 | 1/1/1, 15 ± 5 |
BPC 157 10 μg/kg | 0/0/1a, 5 ± 5a | 0/0/1a, 5 ± 5a |
BPC 157 10 ng/kg | 0/0/1a, 5 ± 5a | 0/0/1a, 5 ± 5a |
Neuronal damage in the karyopyknotic areas (%), mean ± SD (10 HPF, 400 ×) | ||
Control | 27 ± 4 | 23 ± 5 |
BPC 157 10 μg/kg | 0 ± 0a | 0 ± 0a |
BPC 157 10 ng/kg | 0 ± 0a | 0 ± 0a |
Hemorrhage (% of total area), mean ± SD | ||
Control | 0 ± 0 | 0 ± 0 |
BPC 157 10 μg/kg | 0 ± 0 | 0 ± 0 |
BPC 157 10 ng/kg | 0 ± 0 | 0 ± 0 |
Edema (scored 0-3, min/med/max) | ||
Control | 37683 | 37318 |
BPC 157 10 μg/kg | 0/0/1a | 0/0/1a |
BPC 157 10 ng/kg | 0/0/1a | 0/0/1a |
Hippocampus (scored 0-8, min/med/max); percentage of karyopycnotic cells (%), mean ± SD | ||
Control | 37289 | 36924 |
25 ± 3 | 28 ± 2 | |
BPC 157 10 μg/kg | 0/0/0a, 0 ± 0a | 0/0/0a, 0 ± 0a |
BPC 157 10 ng/kg | 0/0/0a, 0 ± 0a | 0/0/0a, 0 ± 0a |
Neuronal damage in the karyopyknotic areas (%), mean ± SD (10 HPF, 400 ×) | ||
Control | 23 ± 2 | 24 ± 3 |
BPC 157 10 μg/kg | 0 ± 0a | 0 ± 0a |
BPC 157 10 ng/kg | 0 ± 0a | 0 ± 0a |
Hemorrhage (% of total area), mean ± SD | ||
Control | 0 ± 0 | 0 ± 0 |
BPC 157 10 μg/kg | 0 ± 0 | 0 ± 0 |
BPC 157 10 ng/kg | 0 ± 0 | 0 ± 0 |
Edema (scored 0-3, min/med/max) | ||
Control | 37683 | 37318 |
BPC 157 10 μg/kg | 0/0/0a | 0/0/0a |
BPC 157 10 ng/kg | 0/0/0a | 0/0/0a |
Hypothalamus (scored 0-8, min/med/max); percentage of karyopycnotic cells (%), mean ± SD | ||
Control | 2/2/2, 31 ± 3 | 1/1/1, 29 ± 4 |
BPC 157 10 μg/kg | 0/0/1a, 5 ± 5a | 0/0/1a, 5 ± 5a |
BPC 157 10 ng/kg | 0/0/1a, 5 ± 5a | 0/0/1a, 5 ± 5a |
Neuronal damage in the karyopyknotic areas (%), mean ± SD (10 HPF, 400 ×) | ||
Control | 24 ± 3 | 28 ± 5 |
BPC 157 10 μg/kg | 5 ± 2a | 6 ± 3a |
BPC 157 10 ng/kg | 5 ± 2a | 6 ± 3a |
Hemorrhage (% of total area), mean ± SD | ||
Control | 0 ± 0 | 0 ± 0 |
BPC 157 10 μg/kg | 0 ± 0 | 0 ± 0 |
BPC 157 10 ng/kg | 0 ± 0 | 0 ± 0 |
Edema (scored 0-3, min/med/max) | ||
Control | 37683 | 37318 |
BPC 157 10 μg/kg | 0/1/1a | 0/1/1a |
BPC 157 10 ng/kg | 0/1/1a | 0/1/1a |
- Citation: Kalogjera L, Krezic I, Smoday IM, Vranes H, Zizek H, Yago H, Oroz K, Vukovic V, Kavelj I, Novosel L, Zubcic S, Barisic I, Beketic Oreskovic L, Strbe S, Sever M, Sjekavica I, Skrtic A, Boban Blagaic A, Seiwerth S, Sikiric P. Stomach perforation-induced general occlusion/occlusion-like syndrome and stable gastric pentadecapeptide BPC 157 therapy effect. World J Gastroenterol 2023; 29(27): 4289-4316
- URL: https://www.wjgnet.com/1007-9327/full/v29/i27/4289.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i27.4289